Clinical experience with romiplostim

Twenty patients with primary immune thrombocytopenia (ITP) received romiplastim as a second line therapy, and 3 patients with secondary thrombocytopenia as off-label. Romiplostim appeared effective in 85 % of patients with both persistent and chronic primary ITP. In patients with resistant and refra...

Full description

Bibliographic Details
Main Authors: G. B. Kuchma, L. K. Kozlova, Ye. Ye. Kuznetsova, S. B. Borisyuk
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/10